Page 7 - Sun Pharma

Sun Pharma aims for market share in all verticals amid Covid-19 situation

The drug major, which has presence in around 150 countries, caters to various various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others

Nifty outlook & stock calls by Anand Rathi: Buy Wipro, Sun Pharma

Wipro's stock has provided breakout from a symmetrical triangle formation on the daily chart with higher than average volumes

Sun Pharma to launch its first innovative product for psoriasis in Japan

Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late

Sun Pharma's diabetes NCE show promise; to go into phase 1 trials in Q3

The stock prices, however, dropped by 3.3 per cent on the BSE at the end of day's trade

Sun Pharma, Hikma ink pact for plaque psoriasis drug for MENA region

One of the company's wholly-owned subsidiaries and Hikma Pharmaceuticals have entered into the agreement for Ilumya, Sun Pharma said in a filing to BSE

Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.

Buy Sun Pharma June Futures at Rs 496: Nandish Shah of HDFC Securities

The stock's primary trend is positive and its price is trading above 200-day SMA

Sun Pharma to test two drugs for treatment of Covid-19, stock up 3.5%

At present there are three clinical trials underway to test nafamostat in Covid19 patients around the world

Sun Pharma to test pancreatitis drug in Covid-19 patients in India

Sun Pharma it has initiated manufacturing of the active pharmaceutical ingredient and the finished product of the drug using technology from its unit, Pola Pharma Japan.

Corona warriors for markets: Ambani, Adani stocks rise most since lockdown

The Bajaj group is the only one on the list of 12 conglomerates to be down - 1 per cent - since the lockdown came into effect, thanks to the hammering of stocks of non-banking financial companies.

Specialty products segment key to Sun Pharma's growth prospects

Pricing pressure in US, lockdown may dent near-term prospects

Sun Pharma up nearly 2% post-March quarter nos; here's what brokerages say

Net profit, too, saw a 37 per cent YoY fall to Rs 399.8 crore, against estimates of Rs 950-1,000 crore.

Sun Pharma's Q4 pre-tax profit down 17% at Rs 577 cr on multiple one-offs

Revenues in the US market, its largest geography, came in at $375 million down 15 per cent, though the year ago period had a high base due to a one-time contribution of specialty products

Sun Pharma Q4 profit declines 37% to Rs 399 cr on one-time exceptional loss

The company had posted a net profit of Rs 635.88 crore in the same period previous fiscal, Sun Pharma said in a BSE filing

Market Ahead, May 27: All you need to know before the opening bell

Today, a total of 21 companies, including Dabur India, Sun Pharma, and United Spirits are scheduled to announce their results.

Covid-19 crisis prompts India to look for global partners in health care

Medical devices industry has potential to attract Rs 70,000 crore in 5 years

Strength in Nifty only above 9,300 levels: Gaurav Garg of CapitalVia

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor

Broad-based rally possible once Nifty crosses 9,450: Angel Broking

At present, traders are advised to stay light and should ideally continue focusing on individual stocks

Two stocks that Vaishali Parekh of Prabhudas Lilladher is bullish on

For HUL's stock, the bias has improved a lot and the stock has the potential to rise further

Top stock picks by CapitalVia Global Research: Buy Sun Pharma, Lupin

Technical Calls by Gaurav Garg, Head of Research at CapitalVia Global Research Limited- Investment Advisor